Marie‐Ange Mouret‐Reynier

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer

Andreas du Bois, Anne Floquet, Jae‐Weon Kim et al. · Journal of Clinical Oncology · 2014 · 328 citations · Full text

Medicine, Oncology, Pharmacology +17

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

Domenica Lorusso, Marie‐Ange Mouret‐Reynier, Philipp Harter et al. · International Journal of Gynecological Cancer · 2023 · 60 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database

Marcela Carausu, Matthieu Carton, Amélie Darlix et al. · ESMO Open · 2021 · 47 citations · Full text

Medicine, Biostatistics, Oncology +17

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609)

Florence Lerebours, Sofía Rivera, Marie‐Ange Mouret‐Reynier et al. · Cancer · 2016 · 40 citations · Full text

Medicine, Endocrinology, Oncology +17